NYSE:ADCT - New York Stock Exchange, Inc. - CH0499880968 - Common Stock - Currency: USD
2.15
-0.19 (-8.12%)
The current stock price of ADCT is 2.15 USD. In the past month the price increased by 74.8%. In the past year, price decreased by -41.58%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18 | 327.00B | ||
AMGN | AMGEN INC | 13.25 | 147.86B | ||
GILD | GILEAD SCIENCES INC | 14.1 | 135.84B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 114.96B | ||
REGN | REGENERON PHARMACEUTICALS | 13.87 | 66.38B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.94B | ||
ARGX | ARGENX SE - ADR | 98.52 | 35.31B | ||
ONC | BEIGENE LTD-ADR | 5.89 | 25.53B | ||
BNTX | BIONTECH SE-ADR | N/A | 24.45B | ||
NTRA | NATERA INC | N/A | 21.01B | ||
BIIB | BIOGEN INC | 8.25 | 19.13B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.11B |
ADC Therapeutics SA is a clinical-stage biotechnology company. The company is headquartered in Epalinges, Vaud and currently employs 263 full-time employees. The company went IPO on 2020-05-15. The company develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. The company employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The firm has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. The company serves customers in the United States, Switzerland, and the United Kingdom.
ADC THERAPEUTICS SA
Biopole, route de la Corniche 3B
Epalinges VAUD 1066 CH
CEO: Christopher Martin
Employees: 264
Phone: 41216530200
The current stock price of ADCT is 2.15 USD. The price decreased by -8.12% in the last trading session.
The exchange symbol of ADC THERAPEUTICS SA is ADCT and it is listed on the New York Stock Exchange, Inc. exchange.
ADCT stock is listed on the New York Stock Exchange, Inc. exchange.
12 analysts have analysed ADCT and the average price target is 8.36 USD. This implies a price increase of 289.02% is expected in the next year compared to the current price of 2.15. Check the ADC THERAPEUTICS SA stock analysts ratings, price target forecast and up-and down grades for more detailed information.
ADC THERAPEUTICS SA (ADCT) has a market capitalization of 213.24M USD. This makes ADCT a Micro Cap stock.
ADC THERAPEUTICS SA (ADCT) currently has 264 employees.
ADC THERAPEUTICS SA (ADCT) has a support level at 1.25 and a resistance level at 2.34. Check the full technical report for a detailed analysis of ADCT support and resistance levels.
The Revenue of ADC THERAPEUTICS SA (ADCT) is expected to grow by 4.15% in the next year. Check the estimates tab for more information on the ADCT EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ADCT does not pay a dividend.
ADC THERAPEUTICS SA (ADCT) will report earnings on 2025-08-04, after the market close.
ADC THERAPEUTICS SA (ADCT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.45).
The outstanding short interest for ADC THERAPEUTICS SA (ADCT) is 6.22% of its float. Check the ownership tab for more information on the ADCT short interest.
ChartMill assigns a technical rating of 6 / 10 to ADCT. When comparing the yearly performance of all stocks, ADCT is a bad performer in the overall market: 65.2% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to ADCT. ADCT may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months ADCT reported a non-GAAP Earnings per Share(EPS) of -1.45. The EPS increased by 47.27% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -49.02% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 87% to ADCT. The Buy consensus is the average rating of analysts ratings from 12 analysts.
For the next year, analysts expect an EPS growth of 9.95% and a revenue growth 4.15% for ADCT